Company intelligence / Profile preview

Shanghai Bowei Biopharmaceutical

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

Shanghai Bowei Biopharmaceutical is a clinical-stage Chinese biotechnology company specializing in the development and commercialization of recombinant vaccines. The company's primary focus is on its virus-like particle (VLP) technology platform, which it utilizes to develop high-valence vaccines against Human Papillomavirus (HPV). Its lead candidate is a 9-valent HPV vaccine currently in Phase 3 clinical trials, positioning the company as a significant domestic competitor in the Chinese vaccine market. Beyond HPV, Bowei is expanding its pipeline to include vaccines for other infectious diseases such as shingles and respiratory syncytial virus.

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Beyond the preview

Go deeper on Shanghai Bowei Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shanghai Bowei Biopharmaceutical.

Explore the full profile